Neurodegenerative diseases (ND) have become a major public health challenge, placing a heavy burden on healthcare systems worldwide. Despite decades of intensive research, relatively few treatments are currently available for the disease, which only provide symptomatic relief. Therefore, high-throughput model systems that recapitulate key features of human neurodegenerative diseases are needed to dissect pathological neuronal mechanisms in vivo and enable the identification of potential intervention compounds. As an excellent model organism, C. elegans is widely used for the discovery and validation of new drugs against neurodegenerative diseases. At CD BioSciences, experienced scientists utilize high-throughput automated drug screening systems and are committed to providing our clients with the best drug screening services for neurological diseases.

C. elegans as a Model for Neurological Disease Drug Screening

Mammalian models are powerful but expensive and time-consuming for drug screening. The invertebrate C. elegans is a simple and attractive model system that provides a complementary approach to mammalian models. Methods for modeling C. elegans include knocking down or knocking out specific genes in C. elegans that are homologous to human diseases; replicating in C. elegans the process of some molecular or cellular mechanism of a human disease; and expressing human genes in C. elegans to induce a relevant disease phenotype. Of these, the third approach has been widely used in neurodegenerative disease research.

Fig.1 C. elegans models of neurodegenerative diseases are generally developed by overexpressing pathogenic proteins in different cells. (Ma L, et al., 2018)

The advantages of C. elegans for NDs study and drug screening:

The well-characterized and easily accessible nervous system

The short generation time (~3 days) and lifespan (~3 weeks)

Genetic tractability speeds target identification

Neurons with most of the known neurotransmitters in mammalian nervous system

Well-characterized synaptic interconnections

Visualized neurons with fluorescently labelled in vivo

Amenable to high-throughput and high content screening

Our Services

As experts in the study of C. elegans, our team has gained extensive experience in the use of microinjection to express specific human genes in C. elegans. CD BioSciences provides high-quality, customized services for neurological drug screening using expertise and proven high-throughput screening platforms to help accelerate your search for new therapies for neurological diseases. Our services include but are not limited to:

Why Choose CD BioSciences?

As a professional C. elegans model service provider, CD BioSciences is dedicated to accelerating our clients' research goals with the most reliable services. If you have any questions about our service, please do not hesitate to contact us for more information.

Reference

1. Ma L, Zhao Y, Chen Y, et al. Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases[J]. European Journal of Pharmacology, 2018, 819: 169-180.

Related Services

• Probiotics Screening Service
• Anti-infective Compound Screening Service
• Pro-longevity Compound Screening Service
• Anti-cancer Drug Screening Service
• Alzheimer's Disease Drug Screening Service
• Parkinson's Disease Drug Screening Service
• Huntington's Disease Drug Screening Service
• ALS Drug Screening Service